| Market Capitalization (Millions $) |
6,959 |
| Shares
Outstanding (Millions) |
38 |
| Employees |
300 |
| Revenues (TTM) (Millions $) |
670 |
| Net Income (TTM) (Millions $) |
244 |
| Cash Flow (TTM) (Millions $) |
370 |
| Capital Exp. (TTM) (Millions $) |
34 |
Shockwave Medical Inc
Shockwave Medical Inc. is a growing medical technology company based in Santa Clara, California, that aims to transform the way cardiovascular diseases are treated. The company specializes in developing products that employ a unique technology known as intravascular lithotripsy (IVL) to treat coronary and vascular calcified lesions.
Founded in 2009 by Dr. John Adams, the company has been successful in raising capital from well-known venture capitalists such as Norwest Venture Partners, Venrock, and Fidelity Management & Research Company, and has been listed on the NASDAQ under the ticker "SWAV" since March 2019. The company's mission is to develop innovative tools to disintegrate calcified arterial plaque, improving patient outcomes and quality of life.
Shockwave's technology, IVL, is a non-invasive, photoacoustic intravascular ultrasound-guided technique that utilizes sound waves to break down calcifications within arteries. The device uses an ultrasound probe to visualize the calcifications and deliver high-frequency sound waves to break them up into small particles that can be naturally eliminated by the body. This process differs from conventional treatment methods such as rotational atherectomy or laser atherectomy, which use a rotating blade or a laser to grind or vaporize plaque.
Shockwave's flagship device is the Shockwave Intravascular Lithotripsy System, which has received regulatory approval in the USA, Europe, and Japan. The device is approved for use in the treatment of severe coronary artery disease (CAD) and peripheral artery disease (PAD) in the lower legs. The Shockwave System has several benefits over conventional approaches to treating calcified lesions, including the ability to treat longer, more complex lesions with less injury to the artery walls and an improved safety profile due to a lower risk of perforation.
The company has amassed positive clinical trial data, including the DISRUPT PAD study, which demonstrated that the Shockwave System improved blood flow in more than 80% of patients with calcified PAD and that the benefits persisted at 12-month follow-up. Additionally, the DISRUPT CAD study suggested IVL was safe and effective in patients with calcified coronary lesions, with a low rate of procedural complications.
In recent years, the company has expanded its product pipeline, including the recent launch of the Shockwave S4 catheter, a next-generation version of the Shockwave Lithoplasty System. The company's sales have been increasing rapidly, and it continues to expand its geographical presence worldwide, with an increasing number of clinicians recognizing the benefits of the Shockwave System.
Overall, Shockwave Medical has established itself as a foremost leader in the field of cardiovascular disease treatment, with an innovative technology and a product portfolio that are poised to have significant impact on the treatment of patients with cardiovascular calcifications.
Company Address: 5403 Betsy Ross Drive Santa Clara 95054 CA
Company Phone Number: 279-4262 Stock Exchange / Ticker: NASDAQ SWAV
| SWAV is expected to report next financial results on February 26, 2024. |
|
|
